Secarna Pharmaceuticals and Scenic Biotech Collaborate on Oligonucleotide Therapy

Secarna Pharmaceuticals GmbH & Co. KG has entered into a discovery and co-development agreement with Scenic Biotech B.V. The partnership aims to develop a disease-modifying oligonucleotide therapy targeting rare genetic disorders. The collaboration will leverage Secarna's OligoCreator® platform and Scenic's Cell-Seq platform to identify and validate novel drug targets with potential applications in broader disease conditions.

Secarna will focus on oligonucleotide discovery, utilizing its AI-enhanced platform to expedite the identification of therapeutic candidates. Scenic Biotech will contribute its expertise in disease biology, enriching the collaborative efforts to develop first-in-class therapies. This joint venture is expected to accelerate the development process, offering potential new treatment options for difficult-to-treat diseases.

Both companies express enthusiasm for the partnership, underlining the synergy between their technologies and capabilities. They aim to tackle challenging diseases by combining their strengths in technology and scientific expertise, potentially benefiting patients with severe genetic conditions.